
Credo and Marvell settle three AEC patent challenges
Credo and Marvell settled three PTAB proceedings over active electrical cables without disclosing terms. The accord clears the petitions, while a separate ITC case remains.
- By
- Nathan Brooks
- Filed
- Channel
- Hardware & Components
- Read
- 3 min read
By Nathan Brooks
Credo Technology Group and Marvell Technology settled their active electrical cable patent dispute on Nov. 17, ending three Patent Trial and Appeal Board proceedings that Marvell filed against Credo patents in August 2025. The agreement covers the two companies’ patent rights in AEC technology.
Credo describes AECs as short copper links that connect servers and switches inside AI data centers. The announcement identified no customer, server platform or deployment volume for the disputed products.
What did the settlement cover?
Credo said in its announcement: “The terms of the agreement remain confidential.” Neither company disclosed a license fee, payment or other financial consideration, so the public record contains no price for the rights exchanged.
Credo called the document an agreement over patent rights, but gave no scope, duration, covered products or ownership detail. Its silence leaves the practical reach of the settlement unmeasured, even though the three disputes themselves are closed.
Marvell had filed inter partes review petitions at the PTAB in August 2025, asking the agency to cancel claims in Credo patents. Those challenges were pending before the U.S. Patent and Trademark Office, according to Credo’s announcement.
The petitions targeted U.S. Patent Nos. 10,877,233, 11,012,252 and 11,032,111. PTAB docket records list all three as terminated after the settlement, rather than decided on their merits. Termination identifies the procedural result, not whether the challenged claims would have survived review.
Investing.com reported that one targeted patent, No. 11,012,252, covers active Ethernet and electrical cable technology. The termination records therefore close the three proceedings without a public ruling on the challenged claims.
What did the market price in?
Credo shares rose about 2% and Marvell shares about 0.5% in after-hours trading on Nov. 17, according to Investing.com. Credo’s percentage gain was roughly four times Marvell’s, though neither market move establishes the value of the patent rights because the terms remain undisclosed.
The restrained reaction fits the limited disclosure. Investors received a settlement, but no royalty schedule, revenue share, patent scope or market forecast. Because no license fee or payment was disclosed, those stock moves cannot be translated into a license rate or expected revenue.
Why does the separate ITC case matter?
Marvell was not a respondent in Credo’s separate U.S. International Trade Commission case over AECs, Investigation No. 337-TA-1446. Credo brought that case in March 2025 against Amphenol, Molex and TE Connectivity, so the Nov. 17 agreement did not end every AEC-related legal action. That proceeding remains separate from the three PTAB petitions settled with Marvell.
In August 2025, Marvell, participating as a non-party, won a ruling disqualifying Credo’s law firm, Fish & Richardson. The ruling concerned counsel eligibility because the firm also represented Marvell in other matters. It was a procedural win, not a judgment on infringement, and no finding on Credo’s enforceability claims against Marvell accompanied that ruling.
What remains unresolved?
In a separate March 2026 development, Credo settled its AEC patent disputes with TE Connectivity and Molex, again on confidential terms. The company said all related lawsuits between those companies would be dismissed.
Marvell, meanwhile, is seeking shareholder support for its $115 billion all-stock deal to buy Lumentum, which has drawn investor pushback. The settlement disclosure does not connect the agreement to that transaction or quantify any effect on Marvell’s AEC business. What it does establish is narrower: three pending petitions ended without a public merits decision.
Credo reports its fiscal second-quarter results on Dec. 1. No AEC capacity, pricing, revenue or shipment figures appear in the settlement announcement or the litigation disclosures, and no analyst estimate is attached to those measures.
For buyers, the immediate competitive question is whether the confidential terms change AEC pricing or product availability. Credo’s fiscal second-quarter report on Dec. 1 is the next scheduled company disclosure, but the settlement provides no guidance on those measures. The legal contest is over; the commercial score remains blank.
Source: mlq.ai
More from Nathan Brooks
Show full bio
Senior reporter covering people, launches and day-to-day practice in Semiconductors, chip manufacturing, hardware, AI compute at Chip Dispatch.
1,056 articles
Related articles
netlist-asks-itc-to-block-imports-of-micron-ai-memory-chips-45745826
Netlist Asks ITC to Block Imports of Micron AI Memory Chips
oura-sues-ultrahuman-again-aiming-to-block-ring-pro-sales-in-u-s
Oura Sues Ultrahuman Again, Aiming to Block Ring Pro Sales in U.S.
qualcomm-seeks-five-year-royalty-relief-in-new-arm-trial-ca5a1430
Qualcomm Seeks Five-Year Royalty Relief in New Arm Trial
apple-reaches-discovery-impasse-with-samsung-epic-and-oura
Apple reaches discovery impasse with Samsung, Epic and Oura



